Core Viewpoint - Pegasus Mercantile Inc. is currently under a Failure-to-File Cease Trade Order (FFCTO) due to its inability to file annual financial statements by the deadline, resulting in a suspension of trading on the Canadian Securities Exchange [1]. Group 1: Default Status Update - The British Columbia Securities Commission (BCSC) issued the FFCTO on February 4, 2026, because the company failed to file its annual financial statements and management's discussion and analysis (MD&A) for the year ended September 30, 2025 by January 28, 2026 [1]. - The FFCTO will remain in effect until the company fulfills all annual financial filing requirements and receives a revocation order from the BCSC [1]. Group 2: Management Actions - The company's management and audit committee are actively working with auditors to complete the necessary documents for the annual financial filings [2]. - The company plans to issue weekly default status reports and confirms that there is no undisclosed material information regarding its affairs [2]. Group 3: Company Overview - Pegasus Mercantile is a prospect generator that supports high-growth companies with financial, operational, and management assistance [3]. - The company is diversifying its focus into sectors such as global wellness, psychedelics, mycology, hemp and CBD, and healthcare-related clinical studies and trials [3].

Core Insights - Charlotte's Web Holdings, Inc. is establishing a Scientific Advisory Board to enhance its medical strategy and support R&D initiatives, expected to begin in September 2025 [1][3][5] Group 1: Company Overview - Founded over a decade ago, Charlotte's Web is a leader in hemp-derived CBD wellness products, emphasizing safety, research, and standardization [2] - The company originated from the development of full-spectrum hemp genetics, which has significantly influenced the hemp health and wellness sector [2] Group 2: Scientific Advisory Board - The Scientific Advisory Board will guide the company's research agenda, clinical initiatives, and the translation of botanical science into patient-centered solutions [1][3] - Dr. Marcel Bonn-Miller, a prominent cannabinoid researcher, will lead the board, bringing over 20 years of experience and numerous published research papers [4][5] Group 3: Medical Channel Strategy - The company aims to scale its medical channel strategy, focusing on product formulations and practitioner education to meet the growing demand for clinically relevant CBD solutions [3][5] - Initiatives include creating Continuing Medical Education (CME) content for healthcare professionals to address gaps in patient care related to pain, anxiety, and sleep issues [3][5] Group 4: Partnerships and Clinical Trials - Charlotte's Web is collaborating with DeFloria, Inc. and Ajna BioSciences PBC to develop AJA001, a full-spectrum CBD extract for treating irritability associated with autism spectrum disorder, which has received FDA approval for Phase 2 clinical trials [3]